

Cal
SB

February 27, 1974

E. N. Terry, M.D.
Pharma-Research Canada
Pointe Claire 730, P.Q.

Dear Skitch,

I am embarrassed that we have completed the data analyses, but have not sat down to write the updated report. The new analyses confirmed the relationship between PRF-36-CL and amphetamine, and after the consultants were happy with the results, we were so pleased that we immediately used the data analysis model for two other studies-- the withdrawal of hashish in chronic smokers, and the relationship of EEG and blood level data in volunteers receiving diazepam or bromazepam. These analyses have been completed and again we are delighted with the results, suggesting that the use of the stepwise linear regression model may indeed be helpful.

I have asked my staff to update the report on PRF-36-CL within the next two weeks. Should this be time enough for your FDA submission, I would ask you to wait. If not, you may wish to add these data as a supplement.

I am most grateful for your support and confidence in these exercises. I believe we have learned a great deal, not only about PRF-36-CL, but about the methodology as well.

My best regards, and my thanks for your patience.

Max
Sincerely yours,

Max Fink, M.D.